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Nanosponges are a novel class of hyper-crosslinked polymer based colloidal struc-
tures consisting of solid nanoparticles with colloidal sizes and nanosized cavities. Well-
-known examples of nanosponges are titanium-based nanosponges (1), silicon nano-
335
Acta Pharm. 63 (2013) 335–358 Review
DOI: 102478/acph-2013-0026





1 C. U. Shah College of Pharmacy
S.N.D.T. Women’s University, Santacruz
Mumbai-400049, India
2 SVKM’s Dr. Bhanuben Nanavati
College of Pharmacy, VileParle
Mumbai-400056, India
Accepted January 29, 2013
Nanosponges are a novel class of hyper-crosslinked po-
lymer based colloidal structures consisting of solid na-
noparticles with colloidal sizes and nanosized cavities.
These nano-sized colloidal carriers have been recently
developed and proposed for drug delivery, since their
use can solubilize poorly water-soluble drugs and pro-
vide prolonged release as well as improve a drug’s bio-
availability by modifying the pharmacokinetic parame-
ters of actives. Development of nanosponges as drug
delivery systems, with special reference to cyclodextrin
based nanosponges, is presented in this article. In the
current review, attempts have been made to illustrate the
features of cyclodextrin based nanosponges and their
applications in pharmaceutical formulations. Special em-
phasis has been placed on discussing the methods of
preparation, characterization techniques and applica-
tions of these novel drug delivery carriers for therapeu-
tic purposes. Nanosponges can be referred to as solid
porous particles having a capacity to load drugs and
other actives into their nanocavity; they can be formu-
lated as oral, parenteral, topical or inhalation dosage
forms. Nanosponges offer high drug loading compared
to other nanocarriers and are thus suitable for solving is-
sues related to stability, solubility and delayed release of
actives. Controlled release of the loaded actives and so-
lubility enhancement of poorly water-soluble drugs are
major advantages of nanosponge drug delivery systems.
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sponge particles (2), hyper-crosslinked polystyrene nanosponges (3) and cyclodextrin-
-based nanosponges (4).
The fundamental appeal of the nanosponge technology arises from the difficulty ex-
perienced with conventional formulations in releasing active ingredients over an exten-
ded period of time. Relatively high concentrations and short duration of action are typi-
cal features of conventional dermatological and personal care products. This might lead
to a cycle of short-term overmedication followed by long-term undermedication. Side
effects such as rash or other serious forms (due to active ingredient penetrating the skin)
are the major drawback of such conventional dermatological and personal care products.
Thus an alternative technology circumventing these drawbacks was the need of the
hour. In recent decades, nanoparticles as drug delivery systems have gained plenty of
attention. Nanotechnology permits even sustained release of actives, compounds and
agents, reducing irritation while maintaining efficacy, thus making nanoparticles a ver-
satile drug delivery vehicle (5, 6). However, only a few nanopreparations, like abraxane,
have reached the market (7). Proteins, peptides, genes, anti-cancer agents and biomo-
lecules have been loaded in nanoparticulate delivery systems and are widely studied so
that the untoward effects may be lowered and efficacy may be improved (8–10). Nano-
particles provide controlled release of entrapped drugs and during this action offer pro-
tection to the drug particle against body conditions maintaining the bioactivity of the
compound. Nanoparticles can be used to localize drugs in the liver, spleen and lungs
since they are readily taken up by the macrophage system (11–15). Tailored coatings
over nanoparticles help overcome reticulo-endothelial uptake of nanoparticles and thus
deliver the drug across various body barriers like BBB (16). Hence, advantages of nano-
particulate drug delivery systems include protection of the trapped drugs, improved ef-
ficacy, lowering of untoward effects, controlled release and drug targeting. Nanoparti-
cles come in the form of polymeric nanoparticles, solid lipid nanoparticles, nanoemul-
sions, nanosponges, carbon nanotubes, micellar systems, dendrimers, etc. Amongst
these, nanosponge (NS) looks like a three-dimensional scaffold possessing a long length
polymer backbone. The polymer in solution form is combined with small molecules
called crosslinkers that act like tiny grappling hooks to fasten different parts of the poly-
mer together. The net effect is formation of spherical particles with hydrophobic cavities
where drug molecules can be entrapped (17). A single nanosponge system consists of a
myriad of interconnecting voids within a non-collapsible structure capable of holding a
wide variety of substances. The outer surface is typically porous, allowing a sustained
flow of substances out of the particle (18). These nano-sized colloidal carriers have been
recently proposed for drug delivery, since their use can solubilize poorly water-soluble
drugs and provide prolonged release, as well as improve the drug’s bioavailability by
modifying the pharmacokinetic parameters of actives (19).
Advantages of nanosponge based drug delivery systems
¿ This technology offers entrapment of ingredients and reduces side effects;
¿ Improved stability, increased elegance and enhanced formulation flexibility;
¿ Extended release with continuous action up to 12–24 hours;
¿ Incorporation of immiscible liquids is possible;
¿ Improved material processing since liquids may be converted to powders.
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Characteristic features of nanosponges
¿ Nanosponges exhibit a range of dimensions (1 µm or less) with tunable polarity
of the cavities. Nanosponges of specific size and adjustable polarity can be syn-
thesized by varying the crosslinker to polymer proportion (20).
¿ They could be either para-crystalline or in crystalline form, depending on the pro-
cess conditions. Crystal structure of nanosponges plays a very important role in
their complexation with drugs. The drug loading capacity of nanosponges mainly
depends on the degree of crystallization. Para-crystalline nanosponges have shown
various drug loading capacities (4).
¿ They are nontoxic, porous particles insoluble in most organic solvents and stable
at high temperatures up to 300 °C (17).
¿ Nanosponges as formulations are stable over the pH range of 1 to 11 and tempe-
rature up to 130 °C (36).
¿ They form clear and opalescent suspensions in water and can be regenerated by
simple thermal desorption, extraction with solvents, by the use of microwaves
and ultrasounds (21).
¿ Their 3D structure enables capture, transportation and selective release of a vast
variety of substances. They can be targeted to different sites due to their ability to
be linked with different functional groups. Chemical linkers enable nanosponges
to bind preferentially to the target site. They form inclusion and non-inclusion
complexes with different drugs (22). Magnetic properties can be also imparted to
nanosponges (by adding magnetic particles into the reaction mixture).
Factors influencing the formation of nanosponges (23)
Polymers and crosslinkers. – The type of polymer used can influence the formation as
well as the performance of nanosponges. Efficient crosslinkers convert molecular nano-
cavities into three-dimensional, nanoporous structures. By tuning the degree of crosslin-
king, either hydrophilic or hydrophobic components that can trap targeted compounds
are formed. Depending upon the nature of crosslinkers, water soluble or insoluble nano-
sponge structures are formed.
Hydrophilic nanosponges are formed when epichlorohydrin (24) is used as crosslin-
ker. Hydrophilic nanosponges can modify the rate of drug release, and can be used to
enhance drug absorption across biological barriers, serving as a potent drug carrier even
in immediate release formulations. Hydrophobic nanosponges can be synthesized using
diphenylcarbonate (4, 19, 20, 28, 29, 34) or pyromellitic anhydride (32), diisocyanates
(31, 55), carbonyldiimidazoles (19, 30, 35) and other crosslinkers and may serve as sus-
tained release carriers for water-soluble drugs including peptide and protein drugs (20).
A list of polymers with their applications is given in Table I.
Apart from the nature of polymer and crosslinker, the type of the drug to be en-
trapped and solvent medium used for the method of preparation affect the formation of
nanosponges.
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Table I. Polymers and their potential applications































































Types of drugs and medium used for interaction. – Drug molecules to be complexed
with nanosponges should have certain characteristics to be successfully entrapped in na-
nocavities. Molecules possessing molecular mass between 100 and 400 Da and having
less than five condensed rings can be easily trapped in the nanocavity of sponges. Also,
these molecules should be less than 10 mg mL–1 soluble in water with a melting point
below 250 °C (23). Compounds with high melting points do not have high stability con-
stant values when loaded into nanosponges. Thus, stable complexes between the drug
and nanosponges are not obtained when they are loaded into the drug. Drug loading is
also affected if the drug has a higher melting point. Lower loading of the drug would be
observed with compounds melting at higher temperature. These low loading values
could be attributed to the structural rigidity of the compound. The interaction between
NS cavities and targeted compounds strongly depends on the medium; namely, a hydro-
philic medium will drive the organic guest molecules into hydrophobic cavities, while
an organic solvent tends to release the organic molecules trapped in nanosponges. These
strong attractions between host and guest molecules depend on optimized chemical and
physical interactions such as mutual matching of polarity, size, hydrophobic environ-
ment and structural properties (25).
Complexation temperature. – The stability constant of a complex is dependent on tem-
perature changes. The stability constant and temperature rise are inversely correlated.
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At increased temperature, the magnitude of apparent stability constant decreases due to
reduction in drug/nanosponge interaction forces (17, 26). Hence, a thorough control
over the temperature should be maintained when nanosponges are prepared.
Degree of substitution. – The type, number and position of the substituent on the po-
lymeric molecule affect the complexation ability of nanosponges (26). The type of substi-
tution is important because b-CD derivatives are available in various forms differing in
functional groups present on the surface of the cyclodextrin derivative. When complex-
ed together with the help of a crosslinker, different functional groups would yield differ-
ent types of complexed material (b-CD nanosponges, CD-carbamate nanosponges, CD-
-carbonate nanosponges, etc.)
There is a direct correlation between the number of substitutions present and the
degree of crosslinking. The higher the number of substituents, the greater is the proba-
bility of undergoing higher crosslinking. Higher degree of crosslinking will yield highly
porous nanosponges due to more interconnections between polymers forming a mesh
type network.
The position of substitution depends on the production conditions. A change in the
production process will yield materials with different physicochemical properties due to
occupancy of some different position by the functional group on the parent compound.
For example, when produced under different conditions, the physicochemical properties
of HP-b-CD samples with the same degree of substitution may not be identical owing to
the possible occupancy of hydroxypropyl groups at different positions on the parent CD
molecule. Thus the purity of material can have a significant effect on the final quality of
nanosponges, indicating the significance of the degree of substitution of the polymer.
As mentioned above, the type of polymer determines the type of nanosponges that
can be fabricated. Thus, based on the polymer used, various types of nanosponges can
be developed. The above listed factors have to be considered during the fabrication of
nanosponges. A few well-known examples of nanosponges are titanium-based nanospon-
ges (1), silicon nanosponge particles (2), hyper-crosslinked polystyrene nanosponges (3)
and cyclodextrin based nanosponges (4). Amongst the various types of nanosponges,
cyclodextrin based nanosponges have received great attention and are widely studied.
Further, this review focuses on cyclodextrin based nanosponges for pharmaceutical use.
Cyclodextrin based nanosponges
Being a biodegradable entity, cyclodextrin breaks down gradually in the body. Once
at the target site, other systems generally unload most of the drug (carried or entrapped
by them) in a rapid and uncontrollable fashion. Unlike other systems, nanosponges offer
controlled release of the actives, which is one of the major advantages of such systems
compared to other nanoparticulate delivery systems under development. CD-based na-
nosponges were conventionally used for decontamination of water. However, they have
recently been explored and employed as solubilizing agents or nanocarriers for drug de-
livery in the field of pharmaceuticals (27–29).
The basic physicochemical characteristics of cyclodextrins were discovered in the
early 1950s; since then, their use is a practical and economical way to improve the phy-
sicochemical and pharmaceutical properties such as solubility, stability, and bioavailabi-
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lity of administered drug molecules. The versatile pharmaceutical material cyclodextrins
(CDs) are classified into hydrophilic, hydrophobic, and ionic derivatives (37). Cyclodex-
trins are a family of compounds made up of sugar molecules bound together in a ring
(cyclicoligosaccharides). Enzymatic degradation of starch by cyclodextrin-glycosyltrans-
ferase (CGT) produces cyclic oligomers (38). CDs are non-reducing, crystalline, water
soluble, cyclic oligosaccharides composed of 5 or more anhydrous a-D-glucopyranoside
units (AGU) (39) linked together by a a-1,4-bond (40). Six, seven or eight AGU are gen-
erally present in CDs and are known as a, b and g-CD, respectively. Due to the chair for-
mation of glucopyranose units, cyclodextrin molecules are cone shaped with secondary
hydroxyl groups at C2 and C3 positions extending from the wider edge and primary
hydroxyl groups at C6 exposed from the opposite side of the narrow edge (38, 24). Their
atomic arrangement is such that the inside cavity is hydrophobic, while the outside of
the torus (truncated cone) is highly hydrophilic (31, 25).
CDs have a well-defined cylindrical cone defining a cavity of about 7.9–8 × 10–10 m
deep and 5–10 × 10–10 m in diameter, depending on the number of glucose units (41).
Certain characteristics of a, b and g-CDs are given in Table II (23, 42).
Table II. Characteristics of a-CD, b-CD and g-CD
Characteristics a-CD b-CD g-CD
Molar mass (g mol–1) 972 1135 1297
Depth-height cone (10–10 m) 7.9–8 7.9–8 7.9–8
Internal diameter (10–10 m) 4.9 6.2 7.9
External diameter (10–10 m) 14.6 15.4 17.5
Cavity volume 174 262 472
Water solubility
(g per 100 cm3) at 25 °C
14.5 1.85 23.2
Crystal water (m, %) 10.2 13.2–14.5 8.13–17.7
CDs have a well-defined cylindrical cavity exhibiting an apolar character, accompa-
nied with high electron density and Lewis base properties (37). In essence, CDs have a
cage like structure as shown in Table II. Due to their peculiar shape, CDs are able to
form stable inclusion complexes with molecules of suitable polarity and size in aqueous
solutions. The complexation mechanism does not involve covalent bonds and the main
driving force of complex formation is the release of enthalpy-rich water molecules from
the cyclodextrin cavity.
Many derivatives have been prepared to improve the characteristics of native CDs.
Owing to their ability to complex with a wide range of compounds, CDs have found nu-
merous applications as novel drug carriers (19). These CDs can serve as multi-functional
drug carriers through the formation of inclusion complexes or by formation of CD/drug
conjugates. More than 30 % of novel pharmaceutical products containing CDs are on the
market worldwide (23). CDs and their derivatives have been used as solubilizers to en-
hance the loading capacity of liposomes, microparticles and nanoparticles (22).
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The first studies of the role of CDs in preparation of microparticles were done by
Loftsson and co-workers. Polymeric nanoparticles may also contain CDs: nanoparticles
of poly(butylcyanoacrylate) and modified CDs have been used as matrices to obtain na-
noparticulate systems. Nanospheres and nanocapsules have been also made from CDs
modified on the secondary face with C6 aliphatic esters using the nanoprecipitation
technique (20). Their solubilizing efficiency may be inadequate due to low intrinsic solu-
bility of the drug or the low stability constant of a drug/CD complex; hence, research on
CD complexes is now a challenging field, and innovative nanosponges are a solution to
this challenge. Nanosponges are generally prepared from b-cyclodextrins because,
among the natural (a, b, g) CDs, b-CD has the highest complexing ability and stability
with crosslinking agents. b-CDs have interesting characteristics, which are tuned to form
nanochannels, wherein drugs may be incorporated in the cage as well as its complex
network. Also, cavity dimensions, low cost of production, higher productive rates are
some of the advantages offered by b-CD for the preparation of nanosponges (29). Reac-
tion between different types of CDs and a crosslinker such as a carbonyl or dicarboxy-
late compound has been carried out (22, 43).
Thus, b-cyclodextrin is generally most preferred for nanosponge preparation. There
are various techniques for the preparation of nanosponges from this material. The sub-
sequent section discusses methods used for synthesizing and complexation of these
nanoparticles.
Methods of nanosponge preparation
Cyclodextrin-based nanosponges (NS) may be synthesized by either a melt proce-
dure or solvent method. Briefly, NS are obtained by the crosslinking of different types of
CDs with a carbonyl or a dicarboxylate compound as crosslinker (22). The different
crosslinking agents may dramatically modulate important parameters like swellability
and hydrophilicity/hydrophobicity of the final nanoporous polymer. In the melt me-
thod, the crosslinker is melted along with CDs. All ingredients are finely homogenized
and placed in a 250 mL flask heated at 100 °C and the reaction is carried out for 5 h under
magnetic stirring. The reaction mixture is allowed to cool and the obtained product is bro-
ken down followed by repeated washing with suitable solvents to remove unreacted ex-
cipients and byproducts (Fig. 1).
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Fig. 1. Pictorial representation of the preparation of nanosponges (nanosponges designed in our
laboratory).
In the solvent method, the melting step is eliminated and the crosslinker is solu-
bilized in solvents like dimethylformamide or dimethylsulfoxide (DMF/DMSO). The
polymer is generally mixed with a suitable solvent, particularly a polar aprotic solvent,
followed by addition of this mixture to an excess quantity of the crosslinker. Optimiza-
tion of the process is performed by varying the crosslinker/polymer molar ratio. The re-
action is carried out at temperatures ranging from 10 °C to the reflux temperature of the
solvent, for 1 to 48 h. Preferred crosslinkers for this reaction are the carbonyl compounds
diphenyl carbonate (DPC), dimethyl carbonate (DMC) or carbonyldiimidazole (CDI).
The product is obtained by adding the cooled solution to a large excess of bidistilled wa-
ter. Recovery of the product is done by filtration under vacuum and the product is fur-
ther purified by prolonged Soxhlet extraction (43, 29).
The particles obtained are solid nanoparticles with a spherical morphology that
have a very high solubilizing power for poorly water-soluble molecules by either form-
ing inclusion or non-inclusion complexes. Once the condensation polymerization is
completed, the transparent block of hyper-crosslinked cyclodextrins can be incubated
with the drug for loading.
Size reduction of synthesized nanosponges is carried out using the high pressure
homogenization technique. In this technique, an aqueous suspension of nanosponges is
initially homogenized with an Ultra Turrax for 10 min at fixed speed (rpm). The homoge-
nized suspensions are then transferred into a high pressure homogenizer and subjected
to cycles of homogenization. For example, a 2 % m/V aqueous suspension of swellable
b-CD PAA nanosponges (PAA-NS) was homogenized using an Ultra Turrax (10 min at
24,000 rpm). The homogenized suspensions were then transferred into a high pressure
homogenizer and subjected to 12 cycles of homogenization, that is, 5 cycles at 5,000 psi
for 5 min, followed by 5 cycles at 7,000 psi for 5 min and 2 cycles at 5,000 psi in a recir-
culation mode. The PAA-NS (polyamioamines) aqueous nanosuspensions obtained were
used for characterization and protein complexation studies. The obtained product could
be safely stored in refrigerator at 4 °C without any aggregation (4). Nanosponges with
narrow size distribution can be obtained by this technique.
Nanosponges may be also synthesized using the ultrasonication technique, wherein
polymers are reacted with crosslinkers merely by keeping them under sonication in the
absence of solvents. The method for fabrication of this type of nanosponges is discussed
by Trotta et al. (20). Anhydrous b-CD and diphenyl carbonate were mixed in a 250 mL
flask and the flask was placed in an ultrasound bath filled with water and heated to 90
°C with sonication for 5 h. Subsequent steps for production crystallization and purifica-
tion were similar to those followed for the melt/solvent technique. Ultrasonication
could be replaced by processes involving a high energy input like probe sonication. The
advantage of this method is no use of organic solvents. Ultrasound assisted nanospon-
ges have been synthesized by Trotta et al. using ultrasound probes (20).
Using the listed techniques, nanosponges can be synthesized, crystallized and puri-
fied. Purification of the obtained product is the most important and critical step. Depen-
ding upon the crosslinker used, byproducts of different nature and chemical structure
are formed. Elimination of the formed byproducts is most essential because of the possi-
ble toxicity exerted by the byproduct residues in the final compound/product. Linkage
between two cyclodextrin molecules mainly depends on the type of crosslinker used.
Depending on the crosslinker used, different types of nanosponges (different linkages)
are obtained.
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Various types of cyclodextrin nanosponges depending on the crosslinker
used for nanosponges
CD-based carbamate nanosponges. – CDs are reacted with suitable diisocyanates such
as hexamethylene diisicyanate (HDI) and toluene-2,4-diisocyanate (TDI) in the presence
of DMF solution at 70 °C for 16 to 24 hours under a nitrogen atmosphere. Residual DMF
is removed by thorough washing with acetone and powder of the crosslinked polymer
is obtained. These nanosponges have an ability to bind to organic molecules and have
been largely employed for water purification. For example, nitrophenol is removed from
its water solution even at very low concentrations. The loading capacity for organic mo-
lecules ranges from 20 to 40 mg per cm3. Nanosponges can remove as much as 84 % of
dissolved organic carbon (DOC) from wastewater (44). Owing to this property, they are
used for removing undesirable taste and odorous compounds from water. Compounds
such as geosmin and 2-methylisoborneol have been successfully removed by employing
CD-based carbamate nanosponges (45).
Tang et al. studied CD-based carbamate nanosponges to adsorb aromatic amino ac-
ids (AAA) from phosphate buffer. L-tryptophane, L-phenylalanine and L-tyrosine were
the AAA selected for further investigation. Adsorption efficiencies of AAA onto CD-ba-
sed carbamate nanosponges were in the order L-tryptophane > L-phenylalanine > L-ty-
rosine (46).
CD-based carbonate nanosponges
The main crosslinkers used for preparation of this type of nanosponges are active
carbonyl compounds such as CDI, DPC and trifosgene. The resulting CD nanosponges
exhibit carbonate bonds between two CD monomers. The reaction can be carried out at
room temperature (CDI) or at 80 to 100 °C (DPC) in the presence or absence of a solvent,
i.e., employing either the solvent technique or melt technique (28). Some of the impor-
tant characteristics of carbonate-CD-based nanosponges are adjustable polarity and
changeable dimensions of their cavities. They can be obtained in different forms, like
amorphous or semicrystalline, by carrying out the reaction under different conditions.
An amorphous crosslinked polymer is formed using the solvent method and a crystal-
line product is obtained when the melt technique is applied.
Carbonate-CD-based nanosponges have been used to encapsulate many drugs such
as paclitaxel, camptothecin, dexamethasone, flurbiprofen, doxorubicin hydrocloride,
itraconazole, 5-fluorouracil, cilostazol, progesterone, oxcarbamazepine, nelfinavir mesy-
late, resveratrol, and tamoxifen. Nanosponges particularly improve the wetting and so-
lubility of these poorly water-soluble drugs. Carbonate nanosponges do not signifi-
cantly affect the surface tension of water. They are non-hygroscopic in nature and they
retain their crystal structure during absorption and desorption of moisture (28).
A unique feature of CD-based carbonate nanosponges is that their ability of solubi-
lity enhancement depends significantly on their degree of crystallinity. For example, the
well-known anticancer drug dexamethasone is fourfold better solubilized by crystalline
nanosponges, whereas the widely used antiviral compound acyclovir is solubilized
twice as much by amorphous nanosponges (43).
343
G. Tejashri et al.: Cyclodextrin based nanosponges for pharmaceutical use: A review, Acta Pharm. 63 (2013) 335–358.
CD-based ester nanosponges
A suitable dianhydride such as pyromellitic anhydride is used as a crosslinking
agent for fabrication of these nanosponges. The exothermic crosslinking reaction is very
fast (completed within a few minutes) and is carried out at room temperature, dissolv-
ing the CD and the dianhydride in DMSO in the presence of an organic base such as
pyridine or triethylamine (to accelerate the reaction in a forward direction). This type of
nanosponges can host both apolar organic molecules and cations simultaneously since it
contains a polar free carboxylic acid group (28). The ionic moiety of NS-PYR complexes
with a large number of heavy metal cations such as Al, Mn, Co, Ni, Cu, Zn, Cd, Pd and
U at different pH values. Different pH values influence cation exchange and coordinate
properties, enhancing the complexing activity of the native CD toward metal ions.
Mele and co-workers studied the inclusion abilities of NS-PYR using a high resolu-
tion magic angle spinning (HR MAS) NMR technique. Water diffusivity and the interac-
tion of fluorescein in inner cavities of nanosponges were thus investigated (33).
Polyamidoamine nanosponges
These types of nanosponges are prepared by carrying out the reaction in water.
b-CD polymerizes with acetic acid 2,20-bis(acrylamide) after long standing (i.e., 94 h at
room temperature). They swell in water (pH dependent behavior) and have both acid
and basic residues. The polymer forms a translucent gel instantly on contact with water.
Time-dependent swelling studies in biorelevant media confirmed the stability of the gel
for up to 72 h. The studies were carried out using albumin as a model protein exhibiting
very high encapsulation efficiency, around 90 %. In vitro drug release studies showed
that protein release can be modulated up to 24 h. Sodium dodecyl sulphate (SDS PAGE)
technique was used to investigate the stability of the product. Conformational stability
of the protein, examined using the SDS PAGE technique, showed that the formulation
was stable for as long as several months (33).
Modified nanosponges
Classical carbonate based nanosponges have been modulated by varying the reac-
tion conditions to better fit the application selected. Fluorescent derivative has been ob-
tained by reacting carbonate nanosponges with fluorescein isothiocyanate in DMSO at
90 °C for a few hours. Fluorescent nanosponges have found their use in biological stud-
ies such as cancer therapy. In a similar manner, carboxylated nanosponges can be ob-
tained using a cyclic organic anhydride such as succinic anhydride or maleic anhydride
(47). These nanosponges react with biologically important carriers such as biotin, chi-
tosan, or proteins, possibly providing a promising specific receptor targeting activity for
drugs. Powder XRD studies have shown that these nanosponges are amorphous in na-
ture. They are also non-hemolytic and non-cytotoxic. For anti-cancer drugs such as
camptothecin, carboxylated nanosponges appear to be promising safe carriers for drug
targeting (4). Characteristics of various b-CD nanosponge fabrication methods are given
in Table III.
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Loading of drugs into nanosponges
Drug molecules can be inserted into the nanocavities of b-CD and due to further
crosslinking, interactions of the guest molecules with more b-CD units might be obser-
ved. Moreover, the presence of a crosslinked network might also cause nanochannels to
be formed in the NS structure. This peculiar structural organization might be responsi-
ble for the increased solubilization and protection capacities of NSs compared to the par-
ent CD (4).
Nanosponges so developed are suspended within drug dispersions and freeze-
-dried along with the drug candidate. Drug loading may be also carried out by the sol-
vent evaporation technique, in which the drug is dissolved in a suitable organic solvent.
Prepared NSs are added to the above drug dispersion and triturated until the solvent
evaporates. Drug/NS ratio is determined based on the solubility of the drug. For exam-
ple, itraconazole was dissolved in dichloromethane to form a solution. To this solution,
nanosponges were added along with copolyvidonum and triturated until the solvent
evaporated. The drug, nanosponges, copolyvidonum were added in a ratio of 1:1:1
(m/m). The obtained solid dispersion was dried in an oven overnight (at 50 °C and at at-
mospheric pressure) to remove any traces of dichloromethane. The CD/crosslinker ratio
can be varied during the preparation to improve the drug loading and to obtain a tai-
lored release profile.
A suitably developed, fully characterized, drug loaded nanosponge can be used for
numerous purposes in the pharmaceutical industry. For suitable applications in phar-
maceuticals, developed nanosponges need to be fully studied and characterized by vari-
ous parameters.
Characterization of nanosponges
To study the interaction of nanosponges with loaded drugs and to understand the
process of their synthesis, fabrication and design, nanosponges are characterized by the
following parameters.
Phase solubility. – The effect of NSs on drug solubility is investigated by the phase
solubility technique (48). To determine phase solubility constants, excess drug is added
into suitable solvents to obtain saturated solutions. Saturated drug concentration is trea-
ted with varying concentrations of blank nanosponges, 1:1, 1:2, 1:3, etc. As there is an in-
crease in their concentration, more of the drug interacts with NSs. The study is carried
out until equilibrium is obtained. A plot of NS concentration vs. drug concentration is
drawn and the type of plot is defined with the help of the Higuchi and Connors classifi-
cation (49). Obtained stability constant values give an idea about the extent of interac-
tion between nanosponges and the drug. Interaction of the drug with nanosponges can
increase the solubility of poorly water-soluble drugs and thereby their dissolution rate.
Such studies have been carried out for itraconazole loaded cyclodextrin nanosponges
prepared by Shankar et al. Consequently, nanosponges could markedly increase the solu-
bility of molecules with very low aqueous solubility such as anticancer drugs, steroids
and anti-inflammatory drugs (31).
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Saturation state interaction. – UV spectroscopy is used as a tool to carry out the satu-
rated solution interaction study. Increasing concentrations of nanosponge solutions (1–
80 ppm) are added to fixed concentrations of the drug. The samples are kept overnight
for interaction and finally filtered solutions are scanned for lmax and absorbance is mea-
sured. Drug loading is interpreted by taking scans of the formulation in the UV range
and analyzing the shift of the absorbance maxima in the spectra compared to pure drug
(31).
Porosity. – Porosity study is performed to check the extent of nanochannels and na-
nocavities formed. Porosity of nanosponges is assessed with a helium pycnometer, since
helium gas is able to penetrate inter- and intra-particular channels of materials. The true
volume of material is determined by the helium displacement method (50). Owing to
their porous nature, nanosponges exhibit higher porosity compared to the parent poly-
mer used to fabricate the system.
Percent porosity is given by equation (1).
% Porosity (E) =
Bulk volume – True volume
Bulk volume
´ 100 (1)
Average diameter and polydispersity indices of nanosponges. – This is usually determi-
ned using a particle size analyzer applying the principle of dynamic light scattering
(DLS) (also known as photon correlation spectroscopy, PCS) (51–59). With the help of the
autocorrelation function, PCS correlates the intensity variation of scattered light to parti-
cle size (60). PCS/DLS measures the hydrodynamic diameter, i.e., it considers all the
particles under measurement as spherical. DLS/PCS gives the particle size taking into
consideration the effective viscosity, temperature and refractive index of the dispersing
medium. Hence, the measured particle size would be a parameter obtained after consid-
ering all the factors. It is always preferred to have qualitative results as well. Qualitative
analysis of the particles can be carried out by performing scanning electron microscopy
(SEM), transmission electron microscopy (TEM) or environmental scanning electron mi-
croscopy (ESEM) analysis of the sample. Particle size and morphology can be obtained
by dispersing the sample in water or other suitable solvents and further assessing it us-
ing techniques like SEM/TEM/ESEM. For example, nanosponges loaded with paclitaxel
were found to show mononodal particle size distribution of 350 ± 25 nm, with narrow
distribution (polydispersity index, p < 0.2) (34).
Zeta potential. – Zeta potential of any system under investigation is a measure of the
surface charge. Surface charge is the parameter that affects body distribution and inter-
action with the biological environment. Zeta potential measurement involves consider-
ation of the electric potential, i.e., diffusion coefficient and electrophoretic mobility (61).
These values are transformed to zeta potential after calculating them from the Smolu-
chowski equation or Stokes equation. The pH and electrolyte concentration (62, 63) need
to be considered while measuring the zeta potential. Stability of the formed nanopar-
ticles can be estimated by zeta potential assessment. Zeta potential in water should be
about ± 30 mV, which is sufficiently high to give stable nano-suspensions that do not un-
dergo aggregation over time. Cavalli et al. measured the electrophoretic mobility and
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zeta potential using a 90 PLUS instrument. To determine the zeta potential, samples of
nanosponge dispersions were diluted with KCl solution (0.1 mmol L–1) and placed in an
electrophoretic cell, where an electric field of about 15 V/cm was applied (35).
SEM and TEM. – These tools are employed to evaluate the particle shape and size as
described above (4) and to get morphological information related to the drug delivery
system under investigation (64–72). SEM involves imparting conductivity to the devel-
oped particles under vacuum with a focused electron beam. Whenever moist samples
are to be investigated, ESEM can be employed. TEM involves morphology investigation
of particles suspended in liquids. TEM and SEM studies have been carried out by Ansari
et al. for prepared nanosponges. TEM studies carried out by these authors (35) revealed
a regular spherical shape and size of NS. The shape and size of the developed nano-
sponges remained unaffected even after drug encapsulation into the nanosponges.
Fourier transform-infrared spectroscopy (FT-IR). – It serves as a major tool to determine
the presence of functional groups. After polymer synthesis, the appearance of functional
group peaks in the FT-IR spectrum is an indication of the formation of bonds between
two monomer units of the polymer. In FTIR for a crystalline structure, a vibrational
spectrum is obtained (73). FT-IR spectra of dried nanosponges, pure drug and drug loa-
ded nanosponges are taken to understand the interaction. The spectra are obtained in
the wavenumber range of 4000 to 650 cm–1. FT-IR also helps in determining the hydro-
phobic and hydrophilic parts of the developed system. Ansari et al. (35) carried out a
comparison of FTIR spectra of resveratrol and the complex and showed that there were
major changes in the fingerprint region, i.e., 900 to 1400 cm–1 indicating drug loading in
nanosponges.
Differential scanning calorimetry (DSC). – Thermo-analytical methods determine whe-
ther the drug substance undergoes some change before thermal degradation of the de-
veloped delivery system. Change in the drug substance may be in the form of melting,
evaporation, decomposition, oxidation or polymorphic transition indicating complex
formation. The thermogram obtained by DTA and DSC can be observed for broadening,
shifting and appearance of new peaks or disappearance of certain peaks. Absence of the
drug melting peak of the crystal structure in the DSC thermogram is a sign of molecu-
larly dispersed drug within the polymer (74–76). Changes in weight loss can also pro-
vide supporting evidence for the formation of inclusion complexes (4).
Thermal analyses are carried out using a DSC instrument to assess the interaction
pattern, crystallinity and nature of the developed nanosponges. Such studies have been
carried out by Swaminathan et al. to analyze the formed nanosponges. DSC thermo-
grams of the complexes did not show the melting peak corresponding to the drug; this
indicates that the drug is no longer crystalline and confirms its interaction with the NS
structure (28, 31).
Powder X-ray diffraction (P-XRD). – Diffraction peaks for a mixture of compounds
are useful in determining chemical decomposition and complex formation. Complex for-
mation of the drug with nanosponges alters the diffraction patterns and also changes the
crystalline nature of the drug. XRD pattern of the sample is determined as a function of
scattering angle (77). Complex formation leads to a sharpening of the existing peaks, ap-
pearance/disappearance of a few new peaks and shifting of certain peaks. Powder
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X-ray diffractometry can be used to detect inclusion complexation in the solid state.
When the drug molecule is liquid, since liquids have no diffraction pattern of their own,
the diffraction pattern of a newly formed substance clearly differs from that of an
uncomplexed nanosponge. This difference in the diffraction pattern indicates complex
formation. When the drug compound is a solid substance, a comparison has to be made
between the diffractogram of the assumed complex and that of the mechanical mixture
of the drug and polymer molecules.
Thermogravimetric analysis (TGA). – These studies are carried out to understand the
melting point, thermostability and crystalline behavior of the particles (78). Trotta et al.
have shown that in a nitrogen atmosphere, b-CD decomposes in a single step, leaving a
carbonaceous residue, which is thermally stable, decomposing at a slow rate at higher
temperatures. On heating in air, the char is oxidized to volatile products below 600 °C,
leaving a ceramic-like residue stable at 800 °C. The charring process involves opening of
the cyclodextrin rings, followed by a chemical evolution similar to that of cellulose with
loss of the glycoside structure and hydroxyl groups and buildup of unsaturation, car-
bonyl groups and aromatic structures. In an analogous manner, in both atmospheres,
nanosponges decompose in a single step with a maximum rate of weight loss at 320 °C
and form a char stable at 800 °C.
Raman spectroscopy. – Raman spectroscopy is a useful tool for studying molecular
structures because the width and the intensity, as well as the wavenumber of the Raman
peaks, are sensitive to the environmental and conformational changes of the molecules
and to intermolecular interactions. This explores the possibility of describing the behav-
ior of CD-NS on passing from the dry to the swollen state. This further provides infor-
mation on the state of water and the model solute dissolved in water inside the nanopo-
rous network of swollen CD-NS, with particular emphasis on the diffusion phenomena
in the gel-like state (32). Hydration dynamics was investigated by Mele et al. through the
analysis of the vibration modes of O-H and C–H groups decoupled from the back-
ground of bulk water.
Drug loading and drug release kinetics. – The results of drug loading capacity prove
that nanosponges may be used as drug carriers. For loading experiments, an excess of
drug solution is incubated with a water dispersion of cyclodextrin nanosponges (10 %,
m/m). After shaking for 24 h at room temperature, nanosponge aliquots are filtered and
freeze-dried. The lyophilized product is used to determine the amount of drug present
in systems with the help of suitable analytical methods (28). In vitro release kinetics ex-
periments are performed using a multi-compartment rotating cell; an aqueous disper-
sion of nanosponges (1 mL) containing the drug is placed in the donor compartment,
while the receptor compartment, separated by a hydrophilic dialysis membrane, is filled
with phosphate buffer at pH 7.4 or pH 1.2. Each experiment is carried out for 24 h. At
fixed times, the receptor buffer is completely withdrawn and replaced with fresh buffer.
The amount of drug in the medium is determined by a suitable analytical method (29)
and drug release is calculated to determine the release pattern.
Swelling and water uptake. – For swellable polymers like polyamidoamine nanospon-
ges, water uptake can be determined by soaking the prepared nanosponges in aqueous
solvent.
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Swelling and water uptake can be calculated using equations (2) and (3).
Percentage of swelling =
Marking of the cylinder at a specified time point
(Initial marking before soaking)
´ 100 (2)
Percentage of water uptake =
Mass of the hydrogel after 72 h
(Initial Mass of dry polymer)
´ 100 (3)
As mentioned earlier, a fully characterized nanosponge formulation can have nu-
merous applications in the pharmaceutical, water purification and cosmeceutical indus-
tries. A few important applications of nanosponges in pharmaceutical companies and
sectors are listed below.
Applications of cyclodextrin nanosponges in pharmaceuticals
Nanosponges prepared from cyclodextrins are considered to be novel systems that
can be used as drug carriers in pharmaceutical formulations. Molecular encapsulations
of the drug and other modifications with appropriate cyclodextrin based nanosponges
can overcome problems such as insolubility, permeability, sensitivity, etc., and facilitate
safe and efficient delivery of drugs (28). Nanosponges can advantageously carry water
insoluble drugs and BCS (Biopharmaceutical Classification System) based class-II and
IV drugs and can be also used to increase the dissolution rate, solubility and stability of
such drugs. Nanoporous structures enable entrapment of flavors by adsorption and thus
mask unpleasant flavors and also convert liquid substances to solids. Nanosponges can
adsorb odorous material and thereby facilitate its removal from organic materials, water
and other products. Some reports suggest that b-CD based nanosponges can deliver the
drug to target sites three to five times more effectively than direct injections. Particularly
good results were obtained by using carbonate based nanosponges in the delivery of
some anticancer drugs such as paclitaxel and campothecin. Nanosponges are solid in na-
ture and can be easily formulated as oral, parenteral, topical or inhalation dosage forms.
For oral administration, the complexes may be dispersed in matrices of excipients, dilu-
ents, lubricants and anti-caking agents suitable for the preparation of capsules or tablets.
For parenteral administration, the complex may be simply carried in sterile water,
saline or other aqueous solutions. For topical administration, they can be effectively in-
corporated into topical hydrogels. A few examples of b-CD based nanosponges used in
the formulation of some drugs are given in Table IV.
Some specific applications of CD based nanosponges include the following:
Improvement of drug stability. – b-CD units are conjugated with a polymer, where a
number of b-CD units are bound to the same polymer chain. Several b-CD units increase
the stability of the drug complex (24). Further, the polymer may cooperate with the
b-CD moieties in stabilizing the complexes. Such studies have been carried out for pro-
teins and peptides because of their insufficient stability, costly production, immunogenic
and allergic potential as well as poor bioavailability and sensitivity towards proteases
(4). Bovine serum albumin (BSA) proteins in solution are not stable, they are stored in
lyophilized state. However, proteins can get reversibly denatured on lyophilization and
adopt conformation markedly different from the native structure. A major drawback in
350
G. Tejashri et al.: Cyclodextrin based nanosponges for pharmaceutical use: A review, Acta Pharm. 63 (2013) 335–358.
protein formulation and development is the need to maintain its native structure during
processing and long-term storage. In the nanosponge based approach, proteins like BSA
have been well encapsulated in swellable cyclodextrin based poly (amidoamine) nano-
sponges and have increased their stability (33).
Nanosponges as carriers for biocatalysts and in the delivery and release of enzymes, pro-
teins, vaccines and antibodies. – Proteins, peptides, enzymes and derivatives thereof are
used in the biomedical and therapeutic fields. Proteolytic enzymes are used to treat can-
cer or type I mucopolysaccharidosis, while DNA and oligonucleotides are used in gene
therapy. Administration of these molecules presents various problems and limitations
(79). Similarly to protein protection and stability concerns, there are concerns with en-
zyme, vaccine and antibody stability. Proteins and other macromolecules can be carried
and delivered across a biological barrier, targeting them towards the site by adsorbing or
encapsulating them in cyclodextrin nanosponges.
Modulating drug release. – Frequent administration is the major drawback of most of
the conventional, commercially available delivery systems. However, a drug loaded in
the nanosponge structure can be retained and released slowly over time. Hydrophilic
CD NS can modify the rate of drug release, which can be used for enhancement of drug
absorption across biological barriers, serving as a potent drug carrier in immediate re-
lease formulations. Hydrophobic CD NS may serve as sustained release carriers for wa-
ter-soluble drugs, including peptide and protein drugs (23). Nanosponges can be also
used as carriers of drugs such as doxorubicin (an anticancer drug), and they may protect
the drug during its passage through the stomach. This drug is released very slowly at
pH 1.1, whereas release is faster if pH is raised to 7.4.
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Camptothecin for solubility enhancement, hemolytic
activity and cytotoxicity
Paclitaxel for bioavailability enhancement
Tamoxifen for cytotoxicity, doxorubicin hydrochlo-
ride, dexamethasone for drug release studies and




As water pollutants, itraconazole for saturation
solubility studies
30, 31
Pyromellitic anhydride As gelling agent 32
Carbonyldiimidazoles
Reseveratol for cytotoxicity, drug accumulation
in the buccal mucosa of rabbit ex vivo studies and




As polymer (carrier) for maleic anhydride
24
2,2-Bisacrylamido acetic acid
(BAC) or polyamido amine
(PAA)
Bovine serum albumin (BSA) 22, 33
Effective delivery carriers. – Cyclodextrin nanosponges have been used as vehicles for
antitumor drugs such as paclitaxel, camptothecin and tamoxifen which present bioavai-
lability problems because their solubility in water is low or non-existent. The drugs were
incorporated into nanosponges and the study was carried out on various cell lines to in-
vestigate their antiproliferative effect. Complexes showed greater effect than that of the
drug alone (19). Mean absolute bioavailability of paclitaxel increased after its loading in
nanosponges and it was found to be 2.5-fold higher than the plain drug (34). Econazole
nitrate, an antifungal agent used topically to relieve the symptoms of superficial can-
didasis, dermatophytosis, versicolor and skin infections, is available in cream, ointment,
lotion and solution forms. Adsorption is not significant when econazole nitrate is ap-
plied to skin and thus high concentrations of active agents are required to be applied for
effective therapy. To overcome this problem, econazole nitrate nanosponges were fabri-
cated by the emulsion solvent diffusion method and were loaded in hydrogels to form a
local depot for sustained drug release (80, 81).
Solubility enhancement. – The presence of cross-linking and cyclodextrin cavities in
the structure favors interaction with active molecules. These characteristics enable seve-
ral substances to be included and get solubilized in the formed cavities. Inclusion
complexation or solid dispersions with CDs can improve drug solubility or rate of disso-
lution of poorly water-soluble drugs due to the reduction in drug crystallinity. The re-
sulting complex hides most of hydrophobic functionality in the interior cavity of the CD
while hydrophilic hydroxyl groups on the external surface remain exposed to the envi-
ronment; the net effect is that a water soluble complex is formed (82). Among the vari-
ous commercially available CDs, methylated CDs with relatively low molar substitution
are the most powerful solubilizers. CD nanosponges can further enhance drug dissolu-
tion even when there is no complexation. CD nanosponges may also act as release en-
hancers; for example, b-CDs have been reported to enhance the release rate of poorly
soluble drugs like naproxen and ketoprofen (23).
CDs also increase the permeability of hydrophobic drugs by increasing drug solu-
bility and dissolution and thus making them available at the surface of the biological
barrier, wherefrom they partition into the membrane without disrupting the lipid layers
of the barrier. The effect of CD nanosponges on drug solubilization in the case of dexa-
methasone, flurbiprofen and doxorubicin hydrochloride, with different structures and
solubilities were investigated by Trotta et al. Dexamethasone and flurbiprofen are lipo-
philic drugs whose log P values are 1.9 and 4.1, respectively, while doxorubicin hydro-
chloride is a hydrophilic drug with a log P value of 0.25. Improved aqueous solubility of
lipophilic drugs was compared to the hydrophilic drug doxorubicin after the drugs were
loaded into nanosponges. This behavior could be ascribed to the higher number of lipo-
philic sites available for the complexation of lipophilic drugs in comparison with the hy-
drophilic sites on the cyclodextrin cage (19).
Swaminathan et al. have studied nanosponges with itraconazole, a drug with aque-
ous solubility of about 1 ng mL–1 at physiological pH. Incorporation of the drug in na-
nosponges improved the drug’s solubility by 27 times and on adding PVP as an auxili-
ary component in the nanosponge formulation, the solubility was enhanced 55-fold.
Nanosponges could thus increase the bioavailability of itraconazole (31).
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Other applications of nanosponges
Nanosponges based on cyclodextrins can strongly bind organic molecules and are
therefore used to remove organic matter, flavors and odors from water (30). Applying
the principles of size exclusion chromatography, hyper-crosslinked nanosponges have
been used in selective separation of inorganic electrolytes. CD-carbonate nanosponges
have been used as supramolecular reaction media for sensitizing the enantiodifferentia-
ting photoisomerization of cyclooctene and 1,3-cyclooctadiene compounds. Nanospon-
ges exhibited unique photochirogenesis behavior, significantly different from the con-
ventional sensitizer-modified CD nanoporous structure (86).
The ability to entrap organic molecules can be ascribed both to the pores generated
by the polymerization reaction and to the CD cavities and the swelling property upon
absorption of water (86). Three-dimensional nanosponges play an important role in the
fractionalization of peptides for proteomic applications. Nanosponges can be used as
carriers for gases such as oxygen and carbon dioxide and could be useful for many bio-
medical applications (28). Nanosponges can selectively soak up biomarkers for diagno-
ses of various disease conditions and can be also used for carrying fluorescent dyes and
other agents (83).
CONCLUSIONS
In the light of such findings, it may be concluded that cyclodextrin-based nano-
sponges are a novel class of biocompatible, versatile crosslinked polymers that greatly
enhance solubility performances of their parent CDs. They are able to include lipophilic
as well as hydrophilic drugs and release them in a controlled and predictable manner at
the target site, thus increasing their bioavailability. By controlling the polymer to cross-
linker ratio, the particle size and release rate can be modulated to better fit the applica-
tion. They could be used to improve the aqueous solubility of lipophilic drugs, and pro-
tect the active moieties from physicochemical degradation. They have been found to be
promising materials for immediate technological use for drug entrapment and as novel
drug carriers. Because of their small size and spherical shape, nanosponges have the po-
tential to be formulated into a wide range of dosage forms such as parenteral, aerosol,
topical, tablets and capsules.
Abbreviations: AAA – aromatic amino acid; AGU – a-D-glucopyranoside units;
BSA – bovine serum albumin; CD – cyclodextrin; CDI – carbonyldiimidazole; CGT – cy-
clodextrin-glycosyltransferase; DLS – differential light scattering; DMF/DMSO – dime-
thyl formamide/dimethyl sulfoxide; DOC – dissolved organic carbon; DPC – diphenyl
carbonate; DSC – differential scanning colorimetry; ESEM – environmental scanning
electron microscopy; FTIR – Fourier transform infrared; HDI – hexamethylene diisicya-
nate; NS – nanosponges; PAA – polyaminoamide; PVA – polyvinyl alcohol; SDS-PAGE –
sodium dodecyl sulphate polyacrylamide gel electrophoresis; SEM – scanning electron
microscopy; SLN – solid lipid nanosuspension; TDI – toluene-2,4-diisocyanate; TEM –
transmission electron microscopy; TGA – thermogravimetric analysis; XRD – X-ray dif-
fraction
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